GLP1R and obesity due to melanocortin 4 receptor deficiency: Additional to the effects on blood glucose, therapy with GLP-1 receptor agonists resulted in beneficial effects on metabolic conditions such as overweight and obesity, beneficial effects on renal and liver function, reduced cardiovascular risk, and also had a positive impact on the treatment of neurodegenerative disorders [6].